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KapLan-Meier analysis of time to death from any 
cause showed significant survival benefit in favor 
of POS (P = 0.035). 
Deaths among patients with probable or proven breakthrough 
IFI during prophylaxis 
Patients with IFI POS (n=7) FLU/ITZ (n =25) 
Total deaths, n (%) 1 (14) 11 (44) 
Cause of death, n (%) 
Progression of IFI 0 8 (32) 
AML/MDS 0 2 (8) 
Intercurrent illness 1 (14) 1 (4) 
Conclusions: In this study, among 32 AML/MDS pa- 
tients with IFIs, mortality rates were high (44% in 
the standard azoLe group and 14% in the POS 
group). An early intervention strategy such as 
POS prophylaxis, which significantly decreases the 
incidence of IFI, may be more effective than wait- 
ing to treat established IFI. 
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Scopulariopsis spp. Invasive Infection in 
Immunocompromised Patients 
H.F. Kennedy*, B.E.S. Gibson, C.L. WiLLiams. 
Department oJ: 44icrobiolog)l, Royal Hospital for 
Sick Children, Yorkhill Division, Glasgow, UK 
Background: The most common disease associa- 
tion of the mould Scopulariopsis is onychomycosis. 
However, in addition, there now exists a smaLL but 
increasing number of reports of invasive infections, 
with high associated mortality, in immunocompro- 
mised patients receiving therapy for malignancies 
or in receipt of bone marrow or solid organ trans- 
plants. 
Objectives: To describe an unusual case of infec- 
tion by Scopulariopsis brevicaulis in a paediatric 
patient with acute [ymphobLastic [eukaemia (ALL) 
and review the Literature on invasive infection 
by Scopulariopsis spp. in immunocompromised pa- 
tients. 
Methods: Case report and Literature review. An- 
tifunga[ MICs were determined at the HPA My- 
cology Reference Laboratory, BristoL, UK. Case: A 
10-year-oLd girl receiving maintenance chemother- 
apy after relapse of ALL foLLowing bone marrow 
transplantation was admitted with fever and a 
dry cough. Her CRP Level was 141 mg/L and her 
absolute neutrophi[ count was 2.1×109/L. BLood 
cultures at this time were negative. ACT  scan 
revealed muLtipLe pulmonary Lesions suggestive of 
funga[ pneumonia. AmBisome was added to em- 
pirical antibiotic therapy. Bronchial [avage was 
not performed. BLood cultures taken 10 days Later 
yielded S. brevicaulis. VoriconazoLe was added 
but blood cultures remained intermittently pos- 
itive. Antifunga[ susceptibility results were then 
received (amphotericin B MIC: 1 mg/L, voricona- 
zoLe: 8 mg/L, itraconazoLe: 16 mg/L, caspofungin: 
4mg/L and terbinafine: 0.5mg/L). The addition 
of oral terbinafine was associated with microbio- 
Logical response and complete resolution of fever. 
AmBisome was Later discontinued and the patient 
discharged. To date, she remains asymptomatic 
and apyrexia[ on oral voriconazoLe and terbinafine. 
However, some pulmonary Lesions remain. 
Results/Conclusions: Review of the Literature in- 
dicates that isolation of Scopulariopsis spp. from 
blood cultures is rare and resistance or reduced 
susceptibility to antifunga[ agents compromises 
therapy of infection. However, in the case pre- 
sented here, blood cultures were positive on 5 oc- 
casions, aLLowing definitive identification and an- 
tifunga[ susceptibility testing, which guided sub- 
sequent therapy. In addition, neutrophi[ counts of 
>1.0×109/L throughout the period of fungaemia 
probably influenced the cLinicaL outcome, which 
was superior to that of the majority of reported 
cases of Scopulariopsis spp. invasive infection in 
immunocompromised patients. 
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Safety of 70% Ethanol as an Antiseptic 
Catheter-lock Solution for Tunneled 
Polyurethane Central Venous Catheters (CVC): 
Randomized Placebo Controlled Trial 
B.J.A. Rijnders*, L. S[obbe. Erasmus University 
Medical Center, Rotterdam, The Netherlands 
Background: Antibiotic-Locks have been shown to 
prevent CVC-reLated bloodstream infection in pts 
with tunneled CVC. An ethanoL-Lock might be a 
good alternative because it has a broad antimi- 
crobia[ spectrum and does not carry the risk of 
selection of antibiotic-resistant microorganisms. 
ObJectives: To evaluate safety and toLerabiLity of 
70% ethanol CVC-Lock. 
Materials & Methods: HematoLogy pts who had 
tunneLLed polyurethane CVC inserted during hos- 
pital stay for chemotherapy were randomized to 
70% ethanol Lock or placebo (NaC[ 0.9%). Lumina 
were Locked for 15rain/day during hospitaLiza- 
tion and 1 ×/week otherwise. EthanoL/pLacebo was 
flushed sLowLy through the CVC afterwards. Liver 
enzymes (g-GT, ASAT) and MCV on cl0 and d14 
were measured and pts were asked to fiLL out a 
questionary on side effects. Recruitment of 440 pts 
is ongoing. This abstract reports on a planned 
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investigator-blinded safety and to[erabi[ity analysis 
when 25% of pts were included. 
Results: As of March 2006, 128 pts were included. 
Complete safety data of 120 pts are available. 
61 of 120 pts had a double lumen CVC, 58 of 120 
pts received ethanol Pts received a mean of 
29.5 locks. Incidence of side effects and laboratory 
abnormalities are given in table 1. g-GF, ASAT and 
MCV on dO as we[[ as after 14 days of locking 
with ethanol vs placebo were comparable between 
groups (p >0.5 for a[[). Overall to[erabi[ity of the 
ethanol locks was good (table 1) but some patients 
had side effects during or immediately after locks 
were flushed through the 2 or 3 [umina. After in- 
clusion of 80 pts this led to an amendment that al- 
lowed pts with side effects to continue on a one lu- 
men only/day regimen. 7 of 128 pts withdrew from 
the study for side effects and after the amendment 
another 3 switched to the one lumen/day regimen 
(stop or switch: 9/64 with ethanol versus 1/64 with 
placebo, p=0.01). 7 of 32 ethanol-lock pts who 
had a triple-lumen CVC stopped or switched to a 
one lumen/day regimen versus 2 of 32 ethanol-lock 
pts with a double-lumen CVC (p=0.1). Serious or 
life-threatening adverse events were not observed. 
Tab[e 1. Incidence of side effects and [aboratory abnorma[ities 
during ethano[ [ock and p[acebo. 
P[acebo Ethano[ 70% p-va[ue 
(n=40 a) (n=49 a 
Nausea/vomiting 9 of 40 I0 of 49 
Changed taste 7 of 40 15 of 49 
Dizziness 5 of 40 6 of 49 
Facia[ flushing 10 of 40 25 of 49 
Drowsiness 5 of 40 13 of 49 
Any side e[[ect 20 of 40 30 of 49 
ASAT (IU) dO: 32, d14:26 dO: 30, d14:28 
gamma-GT (IU) dO: 63, d14:77 dO: 66, d14:87 
MCV of RBC dO: 91, d14:89 dO: 93, d14:89 
)>0.2 
)>0.2 
)>0.2 
)=0.02 
)=0.12 
)>0.2 
) >0.5 b 
)>0.5 b 
)>0.5 b 
aFar the ana[ysis of ASAT, gIGT and MCV data of 120 patients 
were avai[ab[e. The questionary on side effects was returned 
by 89 patients. 
bFor comparisons of dO and d14 data. 
Conclusion: Overall, the administration of a daily 
70%-ethanol catheter-lock was safe and we[[ toler- 
ated and no serious adverse events were observed. 
More pts are needed to prove that the locking 
of only one lumen/day is preferred in pts with a 
triple-lumen CVC. 
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Fatal Varicella-Zoster Virus Infections in 
Immunocompromised Children: Limitation of 
Current Guideline to Prevent Nosocomial 
Infection 
H. Moriuchi*, M. Moriuchi, Y. Funakoshi, M. Okada. 
Nasasaki University Hospital, Japan 
Background: Since varice[[a-zoster virus is very 
contagious and causes serious diseases in the im- 
munocompromised host, prevention of nosocomia[ 
transmission is mandatory. 
Objective: To assess the efficacy of (1) the current 
guideline to prevent nosocomia[ varice[[a-zoster 
virus (VZV) infection and (2) post-exposure mon- 
itoring to promptly discover and treat secondary 
cases. 
Methods: Desisn: A 3.5-year prospective study of 
a[[ nosocomia[ VZV cases with weekly monitoring 
of viremia by real-time PCR. Settins: A 50-bed 
pediatric ward in a University Hospital Patients: 
Approximately 20-30% and 70-80% of beds occu- 
pied by patients with acute illnesses and more 
or less immunocompromised patients with chronic 
illnesses, respectively. Intervention: Among those 
susceptible to VZV or immunocompromised, a[[ in- 
patients on the ward or those who shared the room 
or had contact with the index case received inter- 
vention in case of varice[[a or zoster, respectively. 
Intervention included vaccination for immunocom- 
petent hosts, intravenous immunog[obu[in of high- 
titer neutralizing anti-VZV antibody (VZ-IVIG) for 
immunocompromised hosts within 72h, or 7-day 
course of oral acydovir from the 8th days after 
possible exposure. A[[ patients who received any 
preventive intervention were monitored weekly for 
VZV viremia for 4 weeks. 
Results: We experienced 3 index cases of varice[[a 
and 2 index cases of zoster, followed by 3 secondary 
cases, two of whom died. One survived case re- 
ceived VZ-IVIG, one fatal case received acydovir 
prophylaxis, and the other fatal case did not re- 
ceive any preventive intervention since she was 
believed to have had no direct contact with the 
index case (zoster). In two of the three cases, 
viremia was not detected 4-7 days before onset. 
Conclusions: The current guideline had limited ef- 
ficacy for prevention. Postulated secondary viremia 
may be shorter than expected in the immunocom- 
promised. 
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